Ipragliflozin

Ipragliflozin is a potent and highly selective sodium-glucose cotransporter-2 (SGLT2) inhibitor, demonstrating excellent oral bioavailability with an IC50 of 1,876 nM for SGLT1and 7.38 nM for hSGLT2. Ipragliflozin features dose-dependent pharmacokinetics, effectively induces glucosuria, and has been shown to decrease blood glucose levels, reduce blood pressure, lower body weight, and diminish both hypoglycaemic risk and abdominal symptoms in diabetic patients. Additionally, Ipragliflozin increases insulin levels in the pancreas and prevents the loss of insulin-positive cells in islets of db/db mice. ASP-1941 also maintains a favourable safety profile as monotherapy and is compatible with other hypoglycaemic agents, such as sulphonyl urea, metformin, pioglitazone, and dipeptidyl peptidase-4 (DPP4) inhibitors. Ipragliflozin has been considered as an anti-obesity and anti-diabetic agent.